That’s when the company will hold its HTG Therapeutics key opinion leader webinar. The title of this presentation is “The Role of RNA Profiling in Drug Discovery and Analysis.” The webinar will start at 11:00 a.m. Eastern with Dr. Robert Spitale leading the presentation.
To go along with that, HTG Molecular Diagnostics intends to share information from its transcriptome-informed drug discovery process. It will show how RNA profiling can help in understanding “post-target engagement consequences.”
What’s Happening With HTGM Stock Today?
Ahead of this presentation, shares of HTGM stock are seeing extra trading activity. As of this writing, more than 82 million shares of the stock have changed hands as of this writing. That’s a massive boost compared to the company’s daily average trading volume of about 830,000 shares.
Investors will note that HTGM’s market capitalization of $14 million, trading volume and share price of about $1.28 make it a penny stock. This opens shares up to heavy volatility. It could be that the recent webinar news is acting as a catalyst for retail traders to boost the stock today. Traders will want to be careful about taking a stake in the company as the potential for a retreat seems strong.
HTGM stock is up 163% as of Monday morning.
Investors seeking more of the latest stock market news are in luck!
InvestorPlace has them covered will all of the hottest stock market news for Monday! That includes why shares of Rivian (NASDAQ:RIVN), Faraday Future (NASDAQ:FFIE) and Qualcomm (NASDAQ:QCOM) are on the move. You can learn more at the following links!
More Monday Stock Market News
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.